Tag: biotechnology

120

FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel ...

NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

177

Median survival of top 100 patients is 40.5 months,Median survival of all 331 patients is 23.1 months, Longest survivors have ...

LexaGene Enters Collaboration to Incorporate Cancer Sequencing Technology into a New Product

130

BEVERLY, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for ...

Q BioMed Inc. Prices $5.5 Million Public Offering

112

Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018 NEW YORK, January 30, 2018 /PRNewswire/ -- ...

GT Biopharma Announces $7.1 Million Convertible Debt Financing

112

LOS ANGELES, January 23, 2018 /PRNewswire/ -- GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris: GTBP.PA) today announced that it has entered ...

Earth Science Tech Inc. Signs Contract with CDBQ to Advance Phase-2 Rollout on it’s CBD Patents

by Drew Hendricks

111

Aug 01, 2017, ETST, OTC Disclosure & News Service - Hollywood, FL, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Earth Science ...

CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease

by Randy Whitney

119

VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...

Cocrystal Pharma Receives Investment Through Private Placement

by Anthony Ramsumiran

120

BOTHELL, WA and ATLANTA, GA--(Marketwired - Apr 24, 2017) - On April 20, 2017, Cocrystal Pharma, Inc. (OTCQB: COCP) (the ...

Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

by Drew Hendricks

107

ORLANDO, Fla., March 17, 2017, IMUN, (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for ...

ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes

115

St. Marys, West Virginia, March 9, 2017, PKTX ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced the ...

ETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update.

112

Hollywood, March 06, 2017, ETST, (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an ...

CTD Holdings Closes $2 Million Private Placement

109

ALACHUA, FL-- CTDH, (Marketwired - February 23, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that ...

Earth Science Tech, Inc. Enters $60B Pet Industry with its Nutraceutical Scientific High Grade Hemp CBD Oil Intended for Domestic Animals

108

Hollywood, Feb. 16, 2017, ETST,(GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative ...

ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration